Literature DB >> 11584020

Conformational changes in thrombin when complexed by serpins.

J C Fredenburgh1, A R Stafford, J I Weitz.   

Abstract

Thrombin possesses two positively charged surface domains, termed exosites, that orient substrates and inhibitors for reaction with the enzyme. Because the exosites also allosterically modulate thrombin's activity, we set out to determine whether the structure or function of the exosites changes when thrombin forms complexes with antithrombin, heparin cofactor II, or alpha(1)-antitrypsin (M358R), serpins that utilize both, one, or neither of the exosites, respectively. Using a hirudin-derived peptide to probe the integrity of exosite 1, no binding was detected when thrombin was complexed with heparin cofactor II or alpha(1)-antitrypsin (M358R), and the peptide exhibited a 55-fold lower affinity for the thrombin-antithrombin complex than for thrombin. Bound peptide or HD-1, an exosite 1-binding DNA aptamer, was displaced from thrombin by each of the three serpins. Thrombin binding to fibrin also was abrogated when the enzyme was complexed with serpins. These data reveal that, regardless of the initial mode of interaction, the function of exosite 1 is lost when thrombin is complexed by serpins. In contrast, the integrity of exosite 2 is largely retained when thrombin is complexed by serpins, because interaction with heparin or an exosite 2-directed DNA aptamer was only modestly altered. The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584020     DOI: 10.1074/jbc.M108710200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain.

Authors:  Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

2.  Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Authors:  Wei Li; Ty E Adams; Jyoti Nangalia; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

3.  Thrombin inhibition by serpins disrupts exosite II.

Authors:  Wei Li; Daniel J D Johnson; Ty E Adams; Nicola Pozzi; Vincenzo De Filippis; James A Huntington
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

4.  Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

Authors:  Trevor P Baglin; Robin W Carrell; Frank C Church; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

5.  Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

Authors:  Calvin H Yeh; Alan R Stafford; Beverly A Leslie; James C Fredenburgh; Jeffrey I Weitz
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

6.  Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.

Authors:  Zachary M Huttinger; Laura M Haynes; Andrew Yee; Colin A Kretz; Matthew L Holding; David R Siemieniak; Daniel A Lawrence; David Ginsburg
Journal:  Sci Rep       Date:  2021-09-22       Impact factor: 4.379

Review 7.  A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.

Authors:  Michael E O'Brien; Grace Murray; Debananda Gogoi; Azeez Yusuf; Cormac McCarthy; Mark R Wormald; Michelle Casey; Claudie Gabillard-Lefort; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

8.  The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand.

Authors:  Amanda J Boyle; Leigh Ann Roddick; Varsha Bhakta; Melissa D Lambourne; Murray S Junop; Patricia C Liaw; Jeffrey I Weitz; William P Sheffield
Journal:  BMC Biochem       Date:  2013-03-07       Impact factor: 4.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.